Current data are limited regarding the effects of statins in the naturalistic setting of clinical practice. OBJECTIVES: This study sought to determine the effects of statins on the lipid profile and target LDL-cholesterol (LDL-C) attainment in this setting.
METHODS:
Patients newly initiated on atorvastatin, fluvastatin, pravastatin, or simvastatin from 1/99 to 6/99 were retrospectively identified from a southeastern U.S. health plan database. A parallel design incorporated four study arms based on the statin prescribed. Exclusion criteria included statin therapy in the prior 6 months, less than 90 days of statin therapy, switching of statin, use of combination dyslipidemia therapy, or non-continuous enrollment in the health plan. Changes in lipid subfractions and attainment of LDL-C goal based on NCEP ATP II guidelines were evaluated with OLS and logistic regression techniques utilizing clinically relevant covariates. RESULTS: A total of 2,429 patients (age = 62 ± 13 years, 47.8% male) were identified. Comorbidities included 73% hypertension, 24% diabetes, and 34% atherosclerotic vascular disease. Median duration of statin therapy was 19.4 months. Patients receiving atorvastatin had significantly greater mean absolute (and percentage) reductions in LDL-C and triglycerides compared to the other statins in both the unadjusted and adjusted results (all p < 0.05 vs. atorvastatin). Differences in HDL-cholesterol (HDL-C) were small, however, a statistically significant increase was observed with simvastatin compared to atorvastatin (p < 0.05). Also, a significantly greater percentage (unadjusted, adjusted) of patients reached their NCEP LDL-C goal on atorvastatin (74.0%, 73.0%) compared with fluvastatin (52.0%, 51.0%), pravastatin (58.3%, 56.4%) and simvastatin (69.0%, 69.4%), and atorvastatin patients reached goal faster than the other statins (median: 184 days vs. 215-357 days, all p < 0.05 vs. atorvastatin). CONCLUSION: Patients prescribed atorvastatin had statistically significant improvements in LDL-C and triglycerides, though not in HDL-C, compared to those prescribed other statins. In addition, atorvastatin patients attained LDL-C goal more often and in a shorter timeframe. 
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TRENDS IN THE ATTAINMENT OF CHOLESTEROL TREATMENT GOALS: EVIDENCE FROM MANAGED CARE
OBJECTIVES:
The benefits of aggressive lipid-lowering (L-L) therapy among patients with an elevated risk of coronary heart disease (CHD) are well established, but longitudinal data from clinical practice are limited. Our objective was to assess trends in the rate of cholesterol goal attainment (based on NCEP criteria) among moderate-and high-risk patients in a managed care setting. METHODS: A retrospective cohort design was employed using linked pharmacy claims, medical claims, and clinical laboratory data from members of a Northeastern US group model HMO. The study cohort included patients 55+ years of age who were newly treated with L-L drug therapy between 1995 and 1998, had an LDL-C value over 160 mg/dL within 90 days prior to treatment, and had no history of CHD but at least one CHD risk factor other than age. The duration of follow-up was 1 year. RESULTS: A total of 1044 patients were identified. The average age was 68 years and 41% were male. The mean baseline LDL-C level was 197 mg/dL. Most patients (86%) began treatment with a statin, and adherence (evaluated by "covered days") averaged 61%. The mean decline in LDL-C was 25%. Target LDL-C levels were reached by 34% of this population. The rate of LDL-C goal attainment increased from 18% in the 1995 cohort to 46% in the 1998 cohort. The likelihood of reaching goal was positively associated with cohort year (P < 0.01), male gender (P = 0.05), and beginning treatment with a statin (P = 0.04) and negatively associated with initial LDL-C level (P < 0.01). Age and the number of risk factors were not associated with goal attainment. CONCLUSIONS: In this primary prevention population, cholesterol management improved substantially over time. Nonetheless, most patients still did not achieve their target LDL-C levels, indicating that further research is required to identify steps for increasing the effectiveness of cholesterol treatment. Recent studies have shown that reductions in cholesterol levels among patients with coronary heart disease (CHD) reduce mortality. OBJECTIVE: To determine screening rates for hyperlipidemia among health plan members recently hospitalized for CHD. METHODS: Utilizing data from a large managed care company in a major metropolitan area, member data were selected from the health plan pharmacy, medical and labs claims databases from April 1, 1998 to April 1, 2000. Selection criteria included an age of 35 years and older, continuous enrollment in the plan for the previous 24 months, having one or more inpatient claim during November 1, 1998 to November 1, 1999 indicating CHD, and not having a pharmacy claim for a cholesterol lowering medication within 6 months prior to hospitalization. RESULTS: Of the 74,097 plan members enrolled during the study period, 340 members met inclusion criteria. Of these only 7 (2.1%) had prescription claims for a lipid lowering medications within six months prior to the admission date and were eliminated from the analysis. The mean age of the remaining 333 members was 57.6 years (range 35-79). A majority (61.6%, n = 205) of members were male. A total of 436 lab tests for any cholesterol lab value, including total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides, were completed for only 66 (19.8%) of 333 members. The mean number of lab tests for these members was 6.6 (Range 4 to 24).
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ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES
CONCLUSIONS:
The major finding of this analysis was the low percentage of members who received any cholesterol lab test following a hospital admission for CHD. This suggests that the majority of these high-risk patients
